A calorie deficit takes energy away. Building muscle demands it. Whether you can do both at once depends almost entirely on where you're starting from, and the answer for a beginner is not the answer for someone ten years in. Exercise order comes next. The case for doing compound lifts first has nothing to do with those lifts being better. It's about energy: what a squat asks of you versus what a leg extension asks, and what happens to your form once the tank is empty. There are limits to that rule, and they're worth knowing before you treat it as gospel. Then the timeline questions. One listener has a baby on the way and a month with no gym in front of him, and wants to know when "you don't lose it that fast" stops being true. Another is 67. His doctor just told him muscle is the organ of longevity and to start lifting. His adult kids are terrified. Then the peptide mail. What an FDA advisory vote actually does, and what it doesn't. Why a yes vote is not an approval. Who pays for trials on a molecule nobody can patent, and what happens if the answer is nobody. Plus a listener six weeks into treating his own elbow, asking when "we need more human trials" stops being caution and starts being a gate. Corrections & Context We check the big factual claims after every episode. Here's what needs fixing, what needs more context, and what held up. Everything links to a source so you can check us. What we got wrong 1. You can't currently get these peptides from a compounding pharmacy. On air we described the FDA committee's vote as clearing the way for a doctor to write a prescription and a compounding pharmacy to fill it. That isn't where things stand. The Pharmacy Compounding Advisory Committee met July 23–24, 2026 and voted, but an advisory committee vote is not an agency action. Nothing has legally changed. Before any of these substances can be compounded, the FDA has to accept the recommendation and add it to the 503A Bulks List through formal notice-and-comment rulemaking, and that process hasn't started. As of this writing, none of the seven peptides reviewed in July can legally be compounded. → FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do — Mintz (July 29, 2026) → What the Peptide Vote Actually Changes at My Counter (Hint: Not Much, Yet) — Pharmacy Times One thing to separate out: plenty of peptides remain legally compoundable and always have. The seven under review are the exception. 2. The FDA did not lose in court. We said the agency "lost in court" and that's why the peptides came back. No such loss happened. The path back ran through the executive branch: the FDA removed twelve peptides from Category 2 in April 2026 after their nominations were withdrawn, then sent them to the advisory committee. Where compounding has actually been fought in court lately — the Outsourcing Facilities Association suits over GLP-1 shortage delisting — the FDA won. Judges denied the compounders' injunctions in both the semaglutide and the tirzepatide cases. → FDA clarifies policies for compounders — U.S. Food and Drug Administration → Court Backs FDA in Tirzepatide Compounding Case — McDermott 3. "Peptides are not drugs" is backwards. "Peptide" describes a chemical: a short chain of amino acids. "Drug" describes a legal category. Something can be both, and most peptide medicines are. Ozempic and Wegovy are FDA-approved drugs whose active ingredient is a peptide. BPC-157 is also a drug under federal law, just an unapproved one, which is why selling it for human use is illegal. Your body making peptides doesn't change that, any more than your body making cortisol makes prednisone a supplement. This is our own basil-and-nightshade point from the peptides episode, and we dropped it. → Wegovy (semaglutide) prescribing information — FDA → Understanding the Legal Risks of BPC-157 and Other Unapproved Peptides — Holt Law 4. "There are no human trials, and there never will be any" is too strong on both halves. Human studies exist. They're small, old, and mostly unpublished in full. Under the development name PL-14736, BPC-157 went through a safety and pharmacokinetics study in healthy volunteers (Gut, 2003) and a randomized, double-blind, placebo-controlled Phase II study in ulcerative colitis (Gastroenterology, 2005). A Phase I safety trial in 42 volunteers was registered in 2015 (NCT02637284) and cancelled without published results. The most recent human data is a 2025 intravenous safety pilot in two people. Fewer than thirty published human subjects, total. That's a bad number, but it isn't zero, and "no trials" and "almost no data" lead to different conversations. The "never will be" half is fair as far as it goes. A molecule without strong patent protection has little commercial money behind it. But academic and government-funded trials happen all the time. And there's an irony from the committee itself: some members argued that allowing compounding would open the door to more study, while the counterargument is that selling it commercially removes any reason to ever run the trial. → Is BPC-157 safe for use in humans? — InpharmD evidence summary, with primary citations → Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — PubMed 5. The vote was six of seven, not two — and our earlier reporting needs updating too. We've been describing the July meeting as a narrow win for BPC-157 and KPV with the others still pending. The final tally: the committee recommended adding BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax to the 503A list, and voted againstemideltide (DSIP). Two things matter more than the count. The FDA's own scientific reviewers recommended against all seven. And each peptide was judged against one specific medical use — BPC-157 was assessed for ulcerative colitis, not tendons or elbows or recovery. The uses driving all the demand were never on the ballot. → FDA Expert Panel Backs Compounding of Six Peptides — Medscape → FDA briefing documents and meeting materials, July 23–24, 2026 PCAC 6. There is no 300-pound threshold for GLP-1 medications. We talked about eligibility in pounds. The FDA label uses BMI: 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Someone hoping to lose twenty-five pounds may well qualify. Someone who weighs three hundred p...
